Study identifies potential new pathway for drug development
- Details
- Category: Research
A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development. The study appears in PLOS ONE.
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
- Details
- Category: Research
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis.
Clinical trial hits new target in war on breast cancer
- Details
- Category: Research
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
Promising drug slows down advance of Parkinson's disease and improves symptoms
- Details
- Category: Research
Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial, Thomas Jefferson University researchers report in a new study published in the Journal of the Neurological Sciences.
Possible new treatment for Ewing sarcoma
- Details
- Category: Research
Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in the online issue of the journal Oncogene.
New hope for setback-dogged cancer treatment
- Details
- Category: Research
Several drugs companies have ineffectively tried to produce antibodies that bind to the IGF-1 receptor on the cell surface, which has a critical part to play in the development of cancer. Scientists at Karolinska Institutet in Sweden have now ascertained how these antibodies work, and can explain why only some cancer patients are helped by IGF-1 blockers during clinical tests.
Patient's own immune cells may blunt viral therapy for brain cancer
- Details
- Category: Research
Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected. A new study shows that the reason for this is in part due to the patient's own immune system, which quickly works to eliminate the anticancer virus.
More Pharma News ...
- Discovery offers new treatment for epilepsy
- Drug resistance biomarker could improve cancer treatment
- Discovery of molecular pathway of Alzheimer's disease reveals new drug targets
- TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
- Study shows large-scale genomic testing feasible, impacts therapy
- Compound in grapes, red wine could be key to fighting prostate cancer
- A completely new way of delivering anti-cancer drugs